Covid-19 roundup: Amgen joins the race to develop a drug; Doctors, nurses employed by Merck, Lilly, Pfizer can pitch in at the front lines
Joining forces with Seattle-based Adaptive Technologies, Amgen is looking to develop an antibody-based treatment, echoing efforts from companies including Vir Biotechnology and Regeneron.
Adaptive is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
